About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Press Releases
Press Releases
Year
2018
2019
2020
2021
Submit
March 4, 2021
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
March 3, 2021
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
February 23, 2021
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
February 17, 2021
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
January 19, 2021
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
< previous
1
2
